Home Blog Page 1916

Hang Lung Properties’ Malls Deliver Strong Performance During National Day Golden Week

Chinese Mainland Tenant Sales and Footfall Achieve Double-Digit Growth Hong Kong Footfall Shows Steady Uptick


HONG KONG AND SHANGHAI, CHINA – Media OutReach Newswire – 10 October 2025 – Hang Lung Properties Limited (SEHK Stock Code: 00101) (“Hang Lung” or the “Company”) today announced strong preliminary operational results from its properties in the Chinese Mainland and Hong Kong during the first four days (October 1-4) of the 2025 National Day Golden Week. The Company’s Mainland malls demonstrated robust performance with significant growth in both tenant sales and footfall, while its Hong Kong malls also saw a steady increase in visitor traffic.

Strong Performance in Mainland Portfolio with Sales and Foot Traffic Growth

Hang Lung's Chinese Mainland portfolio under the signature
Hang Lung’s Chinese Mainland portfolio under the signature “66” brand is located in nine major cities


Fuelled by a series of engaging marketing campaigns and effective member promotions during the National Day Golden Week, total tenant sales across Mainland malls rose by approximately 15% year-on-year for the first four days. Heartland 66 in Wuhan and Grand Gateway 66 in Shanghai saw particularly strong growth, with tenant sales climbing by over 70% and 50%, respectively. Member sales were also a key driver, with a year-on-year increase of nearly 20% over the four-day period.

Notably, on National Day (October 1) alone, tenant sales across the Mainland portfolio surged by more than 20% year-on-year, with 70% of the Company’s operating malls recording double-digit growth. Heartland 66 in Wuhan hosted the Central China debut of the popular IP “ButterBear” Autumn Baking Workshop, which attracted customer traffic and helped tenant sales more than double compared to the same period last year.

Heartland 66 in Wuhan attracted customer traffic with the popular IP “ButterBear,” with tenant sales on National Day more than doubling from last year
Heartland 66 in Wuhan attracted customer traffic with the popular IP “ButterBear,” with tenant sales on National Day more than doubling from last year

Overall footfall at Mainland malls improved by 3% year-on-year from October 1-4. In particular, Center 66 in Wuxi and Heartland 66 in Wuhan recorded growth of over 20%.

During the first four days of the National Day Golden Week, footfall at Center 66 in Wuxi increased by over 20% year-on-year
During the first four days of the National Day Golden Week, footfall at Center 66 in Wuxi increased by over 20% year-on-year

Tenant Sales ↑ Approx. 15% yoy

  • Heartland 66 ↑ over 70% yoy
  • Grand Gateway 66 ↑ over 50% yoy
Visitor Traffic ↑ 3% yoy

  • Center 66 and Heartland 66 ↑ over 20% yoy

Hong Kong Portfolio Sees Footfall Recovery, Peak Galleria Jumps Over 20%

In Hong Kong, Hang Lung’s retail portfolio recorded a 4% year-on-year increase in footfall during the first four days of the Golden Week, reflecting an improvement in local consumer sentiment. The Peak Galleria performed exceptionally well with footfall surging by 26% year-on-year, contributing significantly to the overall footfall growth.

The Peak Galleria performed exceptionally well during the National Day Golden Week, with footfall increasing by 26% year-on-year during the first four days
The Peak Galleria performed exceptionally well during the National Day Golden Week, with footfall increasing by 26% year-on-year during the first four days

Hashtag: #HangLung

The issuer is solely responsible for the content of this announcement.

About Hang Lung Properties

Hang Lung Properties Limited (SEHK stock code: 00101) creates compelling spaces that enrich lives. Headquartered in Hong Kong and Shanghai, the Company manages a portfolio of over 3.5 million square meters of retail, office, residential, and hotel properties across Hong Kong and the Chinese Mainland.

The Company’s diverse portfolio in Hong Kong includes office towers and malls in prime districts, as well as luxury residential developments in prestigious areas. In the Chinese Mainland, under the signature “66” brand, the Company’s mixed-use and retail developments are regarded as premium landmarks, strategically located in the hearts of key cities of Shanghai, Shenyang, Jinan, Wuxi, Tianjin, Dalian, Kunming, Wuhan, and Hangzhou.

The Company is recognized for pioneering sustainability in the real estate industry, with an MSCI ESG rating of AA and inclusion on CDP “A List” for Climate Change. The Company powers 80% of its operating properties in the Chinese Mainland with renewable energy, with a net-zero commitment by 2050.

At Hang Lung Properties – We Do It Well.

For more information, please visit .

Relativity Celebrates Legal Industry Leaders at the 2025 Innovation Awards

Honoring individuals and organizations going the extra mile to drive progress, spark change and shape the future of the industry

CHICAGO, Oct. 10, 2025 /PRNewswire/ — Relativity, a global legal technology company, today announced the winners of this year’s Innovation Awards at Relativity Fest. The Innovation Awards are an annual celebration of the Relativity community’s brilliant minds and the innovations shaping tomorrow’s legal industry. This year, the Innovation Awards underwent thoughtful transformation to more accurately reflect the evolving needs and priorities of the community.

Relativity
Relativity

“As our industry continues to evolve at a rapid pace, we saw an opportunity to reimagine the Innovation Awards to better reflect that momentum and honor the exceptional individuals and solutions that are pushing the envelope,” said Laurie Usewicz, Chief Partner Officer at Relativity. “In a time marked by constant change, our commitment to celebrating curiosity, creativity and progress remains stronger than ever.”

The 2025 Innovation Awards categories fall into two overarching themes: Best Innovator and Best Innovation. The Best Innovator categories honor the tech mavericks and curious changemakers transforming the industry. The Best Innovation categories honor those organizations solving complex legal data challenges with custom solutions and creative workflows.

Finalists in the Best Innovator categories are decided by a judging committee, and winners are determined through a community vote. Best Innovation category finalists and winners are determined by a combination of a community vote and a judging committee. The winners this year work at, or directly with, law firms, education institutions, financial institutions and consultant management companies. The 2025 Innovation Awards winners are:

Best Innovator Categories

  • Access to Justice: Melissa Weberman, Counsel and Head of eDiscovery & Data Analytics Group, Arnold & Porter Kaye Scholer LLP
  • Customer Experience: Daniel Smith, eDiscovery Consultant, A&O Shearman
  • Legal Education: Andrew Pardieck, Professor, Southern Illinois University Simmons Law School
  • Inclusion: Nicole Allen, E-Discovery of Counsel, Kilpatrick Townsend & Stockton LLP    
  • Stellar Women:Sarah Cole, Director of Client Engagements, Cimplifi

Best Innovation Categories

  • Beyond: CDS Vision Financial Analysis, CDS
  • Organize: eMerge Split!, Troutman Pepper Locke eMerge
  • Discover: HSF Kramer Snap, Herbert Smith Freehills Kramer
  • Act: Allens Chronology Plus, Allens
  • Workflow: Hatch Waxman Pipeline Protection & Redaction Workflow, IntrepidX

Relativity congratulates all submissions for the innovative work delivered in the past year. For more information on the Innovation Awards and its refreshed category descriptions, click here.

About Relativity
Relativity is a global legal technology company that empowers the legal data intelligence community to organize data, discover the truth and act on it. Its extensible, AI-powered platform, RelativityOne, transforms complex data into insights and actions to elevate the practice of law. Leading corporations, law firms and government agencies worldwide rely on Relativity and its robust partner ecosystem to uncover the most relevant and impactful information across a range of legal work. Relativity expands access to technology by providing its platform at no cost to more than 100 academic institutions through its academic program and to more than 90 organizations supporting pro bono legal work through its Justice for Change initiative.

Contact:
pr@relativity.com

Forbidden gates swing open

BEIJING, Oct. 10, 2025 /PRNewswire/ — A report from China Daily:

Lianhe Fanghu, a bronze jar with lotus and crane decorations, on show at the special exhibition, A Century of Stewardship From the Forbidden City to the Palace Museum.
Lianhe Fanghu, a bronze jar with lotus and crane decorations, on show at the special exhibition, A Century of Stewardship From the Forbidden City to the Palace Museum.

Meridian Gate towers above the entrance to the Palace Museum in Beijing, once China’s imperial palace from 1420 to 1911 and also known as the Forbidden City. During the imperial years, numerous royals, high officials and nobles walked through this gate, which stands for solemnity, ritual and order. They stepped into a “forbidden” place, closed to outsiders where the course of their own destinies — and often the fate of the country — was shaped.

In October 1925, a new chapter opened when the Palace Museum was established, unlocking the gates for the public and marking the beginning of a story about custodians devoted to safeguarding and extending an unbroken civilization.

A century later, tourists ascend the Meridian Gate Galleries, a privilege that was unimaginable even for most high officials who passed the doorway in ancient times. Here, a special exhibition A Century of Stewardship: From the Forbidden City to the Palace Museum lifted its curtain in late September and will run until year’s end.

More than 200 carefully chosen exhibits, including paintings, calligraphic works, jade, bronze ware, gold ware, porcelain and architectural components, among others, are on view for the centennial. The exhibition allows people to see not only the panorama of the Forbidden City from above, but also the cultural lineage borne within its walls through centuries of Chinese history.

Its foreword declares: “You will witness how generations devoted themselves to the nation and its cultural legacy — how they explored the civilization of rituals and rites within palace walls and discovered continuity in ancient collections; how they revived forgotten histories through scholarship and awakened silent artifacts to resonant life.”

Truly, a hasty half-day tour of its three galleries feels like time travel through millennia. “Cultural relics are the best records of civilization,” Xu Wanling, the exhibition’s curator, tells China Daily.

“Through relics, we want visitors to see those historic moments and the people behind them.”  

Great miracles

One monumental treasure on view, and perhaps the most famous painting in Chinese history, Along the River During the Qingming Festival, was unrolled for the first time in a decade.

Created by Zhang Zeduan from the imperial painting academy of the Northern Song Dynasty (960-1127), this silk scroll, which measures over 5 meters, depicts the flourishing landscape of the national capital of Dongjing (present-day Kaifeng, Henan province) through vivid portrayals of hundreds of figures, over 100 houses, 25 boats and countless details of urban life.

Seals of nearly 100 collectors, impressed over centuries, testify to the painting’s journey through history.

The scroll was lost during the war that ended the Northern Song Dynasty, stolen from the palace, passed from one literati’s hand to another and from some powerful minister’s residence to the next, before eventually entering the Qing Dynasty (1644-1911) royal collection in the late 18th century.

Yet, turmoil returned. The last emperor Puyi, who continued to live in the Forbidden City in the 1920s after the fall of the monarchy, managed to get the painting out of the palace again. He later took it, along with many other relics, to Northeast China where he presided over a puppet regime under Japanese occupation. Many assumed the painting was lost forever during the chaotic end of his rule.

Against all odds, it resurfaced in 1950. Cultural relic researchers found it in a wooden case abandoned by Puyi when his puppet state collapsed. The painting later returned to the Forbidden City, intact, like a miracle.

From 1960, Feng Zhonglian, a painting expert, spent 20 years painstakingly copying the scroll, working despite her frail health and social upheaval, creating a modern echo of Zhang’s masterpiece.

Her duplicate is displayed alongside the original at the exhibition, adding an extra chapter to its odyssey.

Xu Tong, a researcher from the painting and calligraphy department of the Palace Museum, is in charge of selecting about 30 key works for this exhibition.

“Many relics did not always stay in the palace peacefully,” she says. “The hardships they endured just tell the exceptional history of this museum.”

In the 1930s, as Beijing faced imminent war, Palace Museum employees transported more than 13,000 crates of relics first south, then west. After the war, they retraced their path to return them. Not a single piece was lost during this decades-long trek.

“We cannot explain these miracles. It can only be credited to the blessing on our nation,” Ma Heng, then director of the Palace Museum, wrote in 1947. Now, as some of those once-journeying relics reappear in the centennial exhibition, their presence testifies again to the custodians’ determination.

Devoted protectors

Another highlight, the Tang Dynasty (618-907) painting Five Oxen, embodies a modern tale of perseverance. One of the earliest surviving Chinese paintings drawn on paper, this scroll in the Qing royal collection disappeared after the Eight-Nation Alliance invaded Beijing in 1900.

It surfaced again in the 1950s at a Hong Kong auction. Premier Zhou Enlai then directed efforts to negotiate and buy the painting and some other relics, racing against the clock and making the mission a matter of national urgency.

Xu Bojiao, a banker from a family of cultural relic appraisers, was entrusted with the task.

In a letter written to Zheng Zhenduo, then the country’s cultural heritage administration chief, he said: “One more relic we acquire, one more thing we’ve done for our nation.” This letter is itself displayed in the exhibition.

“We’re not qualified to judge history,” Xu Wanling says. “But people from history have spoken for us.”

“In the early 20th century, when the country endeavored to overcome years of weakness, some cultural relics were lost,” she adds. “Thanks to our predecessors’ efforts, the treasures came back. It’s also a reflection of the times.”

Over 280,000 cultural relics entered the inventory of the Palace Museum after the founding of the People’s Republic of China in 1949.

Xu Tong highlights that Five Oxen also shows state-of-the-art techniques of restoration. When it was unfurled in front of veteran restorer Sun Chengzhi in 1977, it had more than 300 holes and badly faded colors, posing a huge challenge. Through meticulous handwork, Sun fixed it, giving the splendor and honor back to this time-tested treasure.

A similar marvel happened to another Tang exhibit, a guqin (an ancient Chinese plucked seven-string musical instrument) with the resounding name Dasheng Yiyin, or “lingering sound of the great sage”.  

When it was first found a century ago in the Qing royal inventory, it was registered merely as “a broken guqin” because of its poor condition. Its value was only recognized more than 20 years later. After restoration in 1949, it regained recognition as a celebrated Tang-era masterpiece.

Continuity of lineage

In the eastern gallery of Meridian Gate stands a bronze square jar with lotus and crane decoration, or Lianhe Fanghu, at the center, dating back to the Spring and Autumn Period (770-476 BC), or the age of Confucius. It reflects a time when rituals shifted and old hierarchies faltered. Unearthed in 1923 from a tomb in Henan province, it was allocated to the warehouse of the Palace Museum in 1950.

A cast figure of a crane perches on top of the jar with its wings fully spread and its beak slightly open as if about to call. It is surrounded by two layers of flourishing lotus petals. The body is decorated with sacred animals in various shapes.

Late historian Guo Moruo commented: “This artifact made a breakthrough from previous bronze wares, which had been of a solemn atmosphere. Its freshness and vitality also stood for a transforming society.”

To the south lies the Gold Cup of Eternal Territorial Integrity, created during the Qianlong era (1736-95).The vessel reflects the wealth and social stability of the peak time of the Qing Dynasty, whose Emperor Qianlong was an ardent connoisseur of art.

“The pair may reflect different historical backgrounds, but they may share a common wish for prosperity and auspiciousness,” Xu Wanling explains. “They suit this anniversary, which celebrates heritage and looks to the future.”

To the north of the bronze jar, a jade disc known as bi, from about 2,200 years ago, tells another story of blessings and rituals. Through the hole in its center, visitors can have a glimpse of the crane figure as well.

Also from the former Qing royal collection, the jade disc, with a 40-centimeter diameter, is one of the largest heirlooms of its kind in Chinese history.

“By aligning the three pieces along the gallery’s axis, we highlight cultural continuity,” the exhibition curator says. “The royal collection of the Qing Dynasty is part of this lasting legacy of our civilization.”

Yi Peiji, one of the cofounders of the Palace Museum, once said: “The Forbidden City is the repository of thousands of years of Chinese cultural treasures. Since it became a museum, the treasures, which were confined to secret halls for a few, are now shared with the people.”

Today, digitized editions of many highlights appear on screens with naked-eye 3D effects. Yet, while technology impresses, modern visitors may take such wonders for granted. But for those visitors stepping into the Forbidden City for the first time 100 years ago, the visual impact of these long-hidden cultural relics would probably have been overwhelming.

“It’s hard to imagine their excitement,” Xu Wanling says. “But seeing the same objects, we can still feel a resonance with them.”

A porcelain bowl in painted enamel, decorated with mandarin ducks and a lotus pond, was among the relics displayed in the earliest days of the Palace Museum.

Now quietly resting in the gallery, with an old photograph placed behind it, the Qianlong-era bowl retains its vivid colors, unfaded despite the passage of time.

Time seems irrelevant. A century on, visitors may still share a moment of wonder with those early audiences: This saga of civilization endures.

Utility Global and Maas Energy Works Announce Agreement to Develop Dairy Digester-to-Hydrogen Mobility Project in California

Collaboration to deliver deeply carbon-negative hydrogen using dairy biogas to fuel heavy-duty transportation across California

HOUSTON and REDDING, Calif., Oct. 10, 2025 /PRNewswire/ — Utility Global, Inc. (“Utility”), a U.S.-based leader in economical decarbonization technology, and Maas Energy Works (“MEW”), the nation’s leading developer of dairy digester-to-energy projects today announced an agreement to advance the development of the first commercial project in California to use dairy digester biogas for direct hydrogen fuel production. The project will produce deeply carbon-negative hydrogen from water without electricity for the mobility sector, setting a new benchmark for cost-effective decarbonization.

Utility Global and Maas Energy Works Announce Agreement
Utility Global and Maas Energy Works Announce Agreement

The project will be located at a dairy farm complex in California and will integrate dairy digester biogas systems with Utility’s proprietary H2Gen® technology to produce economical clean fuel for heavy-duty transportation. This innovative combination will deliver hydrogen with one of the lowest negative carbon intensity scores in the market and provide a scalable pathway to decarbonize heavy-duty transportation economically. The project has also secured initial offtake at attractive pricing to both partners.

Under the agreement, MEW will develop, build, and operate the anaerobic digesters and associated biogas treatment systems, while Utility will develop and operate the fuel production system. Together, the companies are demonstrating that collaboration across the agriculture and energy sectors can enable economic decarbonization at scale, further supporting the US’s energy independence.

“This project is another breakthrough moment for Utility – proving that hydrogen fuel can be produced economically, without electricity, and at deeply negative carbon intensity – greener than ‘green hydrogen’ from renewable power,” said Parker Meeks, CEO of Utility Global. “Partnering with MEW allows us to unite world-class biogas expertise with our H2Gen® technology to deliver extremely clean fuel at scale and accelerate California’s transition to zero-emission, heavy-duty transportation.”

“Maas Energy Works has always focused on turning dairy manure into biogas and clean energy,” said Daryl Maas, CEO of Maas Energy Works. “Partnering with Utility Global takes that innovation further — producing carbon-negative hydrogen to power the growth of heavy-duty transportation.”

Once operational, the project is expected to produce approximately three tons per day of carbon-negative hydrogen fuel, creating a scalable solution to supply the growing network of hydrogen fueling stations across California. This fuel will play a critical role in enabling zero-emission trucks and buses to meet the state’s leadership in climate and air quality targets.

The Utility Global–MEW collaboration represents an alternative model for the integration of bio-based clean fuels and industrial decarbonization technology. In addition to dairy farms, other sources of biogas like landfills and wastewater plants are also profitable opportunities for H2Gen to provide a practical and economic pathway to produce and decarbonize transportation fuels near the point of use. The project is currently in front-end engineering development, with final investment decision anticipated following completion of feasibility and design studies and finalization of binding offtake agreements in 2026.

About Utility Global
Utility pioneers clean solutions that power the economic energy transition for hard-to-abate industries such as steel, mobility, upstream oil & gas, refining, and chemicals. Utility’s breakthrough H2Gen® technology harnesses energy from industrial off-gases and various biogases to produce high-purity, low-to-negative carbon intensity hydrogen from water, without electricity, using its proprietary electrochemical process. H2Gen systems have been proven to provide the utmost operationally flexible and integrate seamlessly into existing infrastructure, enabling practical, cost-effective decarbonization.

H2Gen also produces a high-concentration CO₂ stream, simplifying and reducing the cost of carbon capture. Designed to be modular, scalable, and with the smallest hydrogen production footprint, H2Gen empowers customers to convert low-value inputs into high-value clean energy, fuels, or feedstocks. This helps heavy industries meet both business and sustainability goals.

Utility is a portfolio company of Ara Partners, a private equity and infrastructure investment firm focused on industrial decarbonization investments. For more information on Utility’s solutions and services details, visit www.utilityglobal.com.

About Ara Partners
Ara Partners is a global private equity and infrastructure investment firm focused on industrial decarbonization. Founded in 2017, Ara Partners seeks to build and scale companies with significant decarbonization impact across the industrial and manufacturing, chemicals and materials, energy efficiency and green fuels, and food and agriculture sectors. The company operates from offices in Houston, Boston, Washington D.C., and Dublin. Ara Partners closed its third private equity fund in December 2023 with over $2.8 billion in capital commitments. As of June 30, 2025, Ara Partners had approximately $6.6 billion of assets under management.

For more information about Ara Partners, please visit www.arapartners.com.

About Maas Energy Works
Maas Energy Works is a family-owned renewable energy business with headquarters in Redding, California. We develop, own, and operate renewable energy facilities by partnering with dairy families to create biogas out of cow manure and other organic wastes. We then use that biogas to generate vehicle fuel, electricity, heat, CO2, and soon, hydrogen. Our founders Daryl and Christianna Maas believe this waste-to-energy transformation demonstrates our belief that God created humanity in His image to redeem and create. Our 215 employees operate with excellence the nation’s largest fleet of over 80 dairy digesters in 9 states. Learn more at www.maasenergy.com.

Photo – https://laotiantimes.com/wp-content/uploads/2025/10/utility_and_maas_announce_agreement.jpg

Logo – https://laotiantimes.com/wp-content/uploads/2025/10/utility_global_2025_logo.jpg

 

ANTHONY, LINDER & CACOMANOLIS, PLLC EXPANDS REACH WITH BILINGUAL BLOG LAUNCH

WEST PALM BEACH, Fla., Oct. 10, 2025 /PRNewswire/ — Anthony, Linder & Cacomanolis, PLLC (“ALC”) a premier international corporate and securities law firm, is excited to announce that its renowned securities law and capital markets blog will now be published in both English and Japanese. This strategic expansion aims to better serve its diverse audience and enhance accessibility to crucial legal insights in the global market.

Key Highlights:

  • Bilingual Publication: The blog will feature articles and insights in both English and Japanese, catering to a broader audience.
  • Established Resource: Launched in 2010, the blog has been published weekly since its inception and is available at www.securitieslawblog.com.
  • Expert Contributions: Laura Anthony, founding partner at ALC, personally researches and writes the blog, earning her the respect of market participants at all levels.
  • Industry Recognition: Securitieslawblog is well-known for providing comprehensive information on capital markets and securities laws, including up-to-date information on regulations, regulatory changes, and market trends.

ALC’s Role in Japanese U.S. Listings:

ALC has become a go-to legal advisor for Japanese companies pursuing U.S. listings on the Nasdaq and NYSE via initial public offerings (IPOs), direct listings, and de-SPAC transactions. The firm has advised on some of the most innovative cross-border offerings to date, including:

  • The first-ever U.S. IPOs on each of the Nasdaq and NYSE involving Japanese common shares, rather than American Depository Receipts (ADRs)—a concept initially championed by ALC several years ago.
  • A strong track record with over a dozen Japanese clients seeking U.S. IPOs on the Nasdaq and NYSE, recognizing Japan as the next U.S. IPO epicenter, surpassing China in favorability in U.S. markets.

Commitment to Client Success:

“We’re honored to serve as counsel to some of the most dynamic companies coming out of Japan,” said Laura Anthony, ALC Founding Partner. “Our work goes beyond legal guidance—we help global businesses realize their growth ambitions through strategic, innovative, and compliant U.S. market access.”

Contact:

Laura Anthony, Founding Partner
Anthony, Linder & Cacomanolis, PLLC
lanthony@alclaw.com

About Anthony, Linder & Cacomanolis

Anthony, Linder & Cacomanolis, PLLC is a leading law firm specializing in securities law and capital markets. With a strong international presence and an unwavering commitment to excellence, ALC continues to lead the way in advising companies navigating the complex intersection of global law and capital markets.  The Anthony, Linder & Cacomanolis team represents issuers and underwriters and has completed transactions valued in excess of $25 billion.  For more information please visit www.alclaw.com or contact us at 844-281-2863.

Celltrion receives U.S. FDA approval for EYDENZELT® (aflibercept-boav), biosimilar referencing EYLEA® (aflibercept)

  • EYDENZELT® is approved for the treatment of patients with neovascular (wet) age-related macular degeneration (wAMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), and diabetic retinopathy (DR)
  • Celltrion plans to enter the U.S. ophthalmology market to meet diverse needs of patients suffering from various eye conditions

INCHEON, South Korea, Oct. 10, 2025 /PRNewswire/ — Celltrion, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved EYDENZELT® (aflibercept-boav), biosimilar referencing EYLEA® (aflibercept), for the treatment of neovascular (wet) age-related macular degeneration (wAMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME) and diabetic retinopathy (DR).[1]

Aflibercept is a VEGF inhibitor formulated as an injection for the eye that blocks the growth of new blood vessels and decreases the ability of fluid to pass through blood vessels (vascular permeability) in the eye by blocking VEGF-A and placental growth factor (PlGF), two growth factors involved in ocular angiogenesis.

“Timely access to effective therapies is essential for individuals affected by retinal diseases. We are proud to have EYDENZELT approved by the FDA, and we look forward to expanding the availability and access of biological treatments across the U.S.,” said Dr. Juby Jacob-Nara, Senior Vice President and Chief Medical Officer at Celltrion USA. “With EYDENZELT demonstrating biosimilarity to its reference product, we believe this approval will mark a significant milestone in the treatment landscape of retinal diseases—helping physicians broaden their options and improving patient outcomes.”

The FDA approval was based on a totality of evidence including analytical, nonclinical, and clinical data. In a randomized, double-masked, parallel-group, multicenter phase III study of EYDENZELT, the efficacy, safety, pharmacokinetics, and immunogenicity of EYDENZELT was compared to EYLEA in patients with diabetic macular edema (DME). The 52-week trial included 348 patients with DME. The primary endpoint was the change in best corrected visual acuity measured at week 8 from baseline, comparing EYDENZELT and EYLEA. Results of the study showed that EYDENZELT met the predefined equivalence criteria, and secondary endpoints of efficacy, safety, and immunogenicity also showed trends similar to EYLEA.

“Advanced age-related macular degeneration (AMD) is a leading cause of irreversible blindness and visual impairment in the world and nearly 20 million people in the U.S. are living with some form of age-related macular degeneration,” said Dr. David M. Brown, Director, Retina Consultants of Texas Research Centers, Co-chair, Medical Leadership Board Retina Consultants of America. “EYDENZELT will be an important new addition to our options for the treatment of our patients with serious retinal diseases.”

EYDENZELT is Celltrion’s first FDA-approved biologic product in ophthalmology. EYDENZELT was also approved by the European Commission (EC) in February 2025.   

###

About EYDENZELT® (aflibercept-boav) 

EYDENZELT® (aflibercept-boav) is a vascular endothelial growth factor (VEGF) inhibitor referencing EYLEA® (aflibercept). EYDENZELT is approved based on a comprehensive data confirming the therapeutic equivalence EYLEA. In the U.S., EYDENZELT is indicated for the treatment of patients with neovascular (wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME) and diabetic retinopathy (DR).

INDICATIONS

EYDENZELT® (aflibercept-boav) is indicated for the treatment of patients with:

  • Neovascular (Wet) Age-Related Macular Degeneration (AMD)
  • Macular Edema Following Retinal Vein Occlusion (RVO)
  • Diabetic Macular Edema (DME)
  • Diabetic Retinopathy (DR)

IMPORTANT SAFETY INFORMATION

  • EYDENZELT is contraindicated in patients with ocular or periocular infections, active intraocular inflammation, and hypersensitivity to aflibercept or any of the excipients in EYDENZELT.
  • Instruct patients and/or caregivers to report any signs and/or symptoms suggestive of endophthalmitis, retinal detachment, or retinal vasculitis without delay and should be managed appropriately.
  • Increases in intraocular pressure have been seen within 60 minutes of an intravitreal injection. Intraocular pressure and the perfusion of the optic nerve head should be monitored and managed appropriately.
  • There is a potential risk of arterial thromboembolic events (ATEs) following intravitreal use of VEGF inhibitors, including aflibercept products. ATEs are defined as nonfatal stroke, nonfatal myocardial infarction, or vascular death (including deaths of unknown cause).
  • The most common adverse reactions (≥5%) reported in patients receiving aflibercept were conjunctival hemorrhage, eye pain, cataract, vitreous detachment, vitreous floaters, and intraocular pressure increased.

For more information, see Full Prescribing Information.

About Celltrion, Inc.

Celltrion, Inc. is a leading biopharmaceutical company that specializes in researching, developing, manufacturing, marketing and sales of innovative therapeutics that improve people’s lives worldwide. Celltrion is a pioneer in the biosimilar space, having launched the world’s first monoclonal antibody biosimilar. Our global pharmaceutical portfolio addresses a range of therapeutic areas including immunology, oncology, hematology, ophthalmology and endocrinology. Beyond biosimilar products, we are committed to advancing our pipeline with novel drugs to push the boundaries of scientific innovation and deliver quality medicines. For more information, please visit our website www.celltrion.com/en-us and stay updated with our latest news and events on our social media: LinkedIn, Instagram, X, and Facebook.

About Celltrion USA

Celltrion USA is Celltrion’s U.S. subsidiary established in 2018. Headquartered in New Jersey, Celltrion USA is committed to expanding access to innovative biologics to improve care for U.S. patients. Celltrion currently has ten biosimilar products approved by the U.S. FDA: INFLECTRA® (infliximab-dyyb), TRUXIMA® (rituximab-abbs), HERZUMA® (trastuzumab-pkrb), VEGZELMA® (bevacizumab-adcd), YUFLYMA®(adalimumab-aaty), AVTOZMA® (tocilizumab-anho), STEQEYMA® (Ustekinumab-stba) STOBOCLO® (denosumab-bmwo), OSENVELT® (denosumab-bmwo), and OMLYCLO® (omalizumab-igec) as well as a novel biologic ZYMFENTRA® (infliximab-dyyb). Celltrion USA will continue to leverage Celltrion’s unique heritage in biotechnology, supply chain excellence and best-in-class sales capabilities to improve access to high-quality biopharmaceuticals for U.S. patients. For more information, please visit www.celltrionusa.com, and stay updated with our latest news and events on our social media: LinkedIn.

FORWARD-LOOKING STATEMENT

Certain information set forth in this press release contains statements related to our future business and financial performance and future events or developments involving Celltrion, Inc. and its subsidiaries that may constitute forward-looking statements, under pertinent securities laws.

These statements may be also identified by words such as “prepares”, “hopes to”, “upcoming”, “plans to”, “aims to”, “to be launched”, “is preparing”, “once gained”, “could”, “with the aim of”, “may”, “once identified”, “will”, “working towards”, “is due”, “become available”, “has potential to”, the negative of these words or such other variations thereon or comparable terminology.

In addition, our representatives may make oral forward-looking statements. Such statements are based on the current expectations and certain assumptions of Celltrion, Inc. and its subsidiaries’ management, of which many are beyond its control.

Forward-looking statements are provided to allow potential investors the opportunity to understand management’s beliefs and opinions in respect to the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not guarantees of future performance and undue reliance should not be placed on them.

Such forward-looking statements necessarily involve known and unknown risks and uncertainties associated with the company’s business, including the risk factors disclosed in its Annual Report and/or Quarterly Reports, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or results expressed or implied by such statements.

Celltrion, Inc. and its subsidiaries undertake no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws.

Trademarks

EYDENZELT® is a registered trademark of Celltrion, Inc.
EYLEA® is a registered trademark of Regeneron Pharmaceuticals Inc.

References

[1] EYDENZELT U.S. prescribing information (2025)

US–24-00028

For further information please contact:
Katie Gallagher
kgallagher@jpa.com
+1 617-657-1324

Alamar Biosciences Launches NULISAqpcr™ BD-pTau217 Assay: A Breakthrough in Non-Invasive, Brain-Specific Biomarker Detection for Alzheimer’s Disease Research

New Blood-Based Assay Delivers Unparalleled Sensitivity and Specificity to enable the next generation of assay development. 

FREMONT, Calif., Oct. 10, 2025 /PRNewswire/ — Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, today announced the launch of the NULISAqpcr™ BD-pTau217 Assay— a transformative leap in blood-based quantification of brain-derived phosphorylated tau 217 (pTau217)—a pivotal biomarker in Alzheimer’s disease research and other tauopathies. This first-of-its-kind assay is the only brain-derived single-plex solution available, setting a new benchmark for precision and CNS specificity in neurodegenerative disease research.

NULISA BD-pTau217 Assays
NULISA BD-pTau217 Assays

Built on Alamar’s proprietary NULISA™ platform, the NULISAqpcr BD-pTau217 Assay delivers unprecedented sensitivity and specificity from non-invasive sample types such as plasma, serum and dried blood spots. The research assay’s direct measurement of CNS-derived pTau217 without the need for cerebrospinal fluid (CSF) collection or PET imaging removes existing barriers to widespread adoption in population-based studies or longitudinal clinical trials.

“The NULISAqpcr BD-pTau217 Assay redefines what’s possible in CNS biomarker quantitation,” stated Dr. Yuling Luo, Founder, Chairman and CEO of Alamar Biosciences. “By removing the noise from the peripheral sources of tau, researchers can now detect meaningful changes in the brain earlier and with higher precision.”

“The performance of Alamar’s brain-specific plasma pTau217 assays is excellent,” said Jonathan Schott, MD, PhD, Professor of Neurology, University College London. “For the detection of Alzheimer’s pathology with cognitive symptoms, our early results suggest that the single-plex format performs at least as well as established plasma ptau217 tests, but has a higher fold-change, and results in fewer samples being classified in the indeterminate range. In a research setting, brain-specific pTaus measured using the multiplex assay show great promise in detecting asymptomatic individuals with high levels of Alzheimer’s pathology who may be candidates for clinical trials of disease modifying therapies.”

Available as a single-plex NULISAqpcr assay or within the multiplex NULISAseq™ CNS Disease Panel 120, the BD-pTau217 assay will support both discovery and translational research. The assay’s automated workflow enables processing of over 220 samples per day with the ARGO™ HT System, making it ideal for high-throughput analysis in disease cohorts or population-based studies. 

Alamar Biosciences continues to collaborate with the neuroscience community to unlock biomarker insights that accelerate progress in Alzheimer’s and beyond. Visit alamarbio.com to learn more.

The NULISA BD-pTau217 Assays are for research use only and not for use in diagnostic procedures.

About Alamar Biosciences, Inc.
Alamar Biosciences is a privately held life sciences company with a mission to power precision proteomics to enable the earliest detection of disease. The company’s proprietary NULISA™ Platform along with the ARGO™ HT System work seamlessly with the latest advances in genomics to achieve single digit attomolar detection sensitivity, greatly surpassing the most sensitive protein detection technology on the market today. For more information, please visit alamarbio.com.


 

Amcor Appoints Stephen R. Scherger as Executive Vice President and Chief Financial Officer

Michael Casamento to return home to Australia to be closer to his family on a full-time basis; Will leave the Company as a result, remaining in an advisory role until June 30, 2026 to support transition

Company reaffirms Fiscal 2026 and first quarter Fiscal 2026 outlook

ZURICH, Oct. 10, 2025 /PRNewswire/ — Amcor (NYSE: AMCR, ASX: AMC), a global leader in consumer packaging and dispensing solutions for Nutrition, Health, Beauty and Wellness, announced the appointment of Stephen R. Scherger as Executive Vice President and Chief Financial Officer, effective Nov. 10, 2025. Mr. Scherger succeeds Michael Casamento, who after ten years as Amcor’s Chief Financial Officer has decided to return home to Australia to be closer to his family on a full-time basis and will leave the Company as a result. Mr. Casamento will remain as an advisor to the Company until June 30, 2026, to help support a smooth transition.

Stephen R. Scherger
Stephen R. Scherger

Michael Casamento
Michael Casamento

Mr. Scherger brings more than 30 years of finance, operations and strategy experience in the packaging industry. Most recently, he served as Executive Vice President and Chief Financial Officer of Graphic Packaging since 2015, where he played a leading role in transforming Graphic Packaging into the world’s largest producer of fiber-based packaging, including supporting the integration and synergy realization for a number of large-scale acquisitions. During his tenure, Graphic Packaging’s net sales more than doubled to nearly $9 billion and net income nearly tripled.

Amcor CEO Peter Konieczny commented, “On behalf of the Board, I’m pleased to welcome Steve to the Amcor team. His deep industry experience, unique understanding of the U.S. and global packaging markets and team-oriented leadership style make him a natural fit for Amcor. His proven track record of enhancing growth and profitability at lean, global businesses will further enhance Amcor’s ability to deliver near- and long-term value for customers and shareholders.”

“It is a privilege to join Amcor as CFO,” commented Scherger. “Amcor has established itself as a global leader and innovator in the packaging industry, especially after the Berry Global acquisition. I am honored and excited to join the team at this time and contribute to delivering the ongoing integration commitments, the identified portfolio optimization and driving long-term organic growth.”

Konieczny continued, “On behalf of the Amcor team, I’d like to thank Michael for more than a decade of service, which concludes with Amcor being better positioned than ever following our successful combination with Berry Global. His contributions and leadership have been outstanding and he has played a significant role in laying the foundation for years of success. We wish him all the best as he returns to Australia.”

Reaffirms Fiscal 2026 and First Quarter Fiscal 2026 outlook 

Amcor reaffirmed its first quarter and fiscal year 2026 outlook, as provided in connection with fourth quarter and fiscal year 2025 financial results on Aug. 14, 2025. The Company continues to expect Adjusted EPS of 80-83 cps, representing 12-17% constant currency growth, and Free Cash Flow of $1.8-1.9 billion for fiscal year 2026.  For the first quarter, Amcor also expects Adjusted EPS to be within the previously announced 18-20 cps range.

About Stephen Scherger

From 2015 to 2025, Mr. Scherger served as Chief Financial Officer of Graphic Packaging (NYSE: GPK), a publicly traded provider of fiber-based packaging solutions to food, beverage, foodservice, and other consumer products companies. From 2014 to 2015 he served as Senior Vice President, Finance of Graphic Packaging and from 2012 to 2014, he served as Senior Vice President, Consumer Packaging of Graphic Packaging, where he had direct responsibility for a $2.1 billion business comprising approximately 6,000 employees and 28 manufacturing facilities. He spent the first 25 years of his career at MeadWestvaco, where he served in finance, operations and strategy roles of increasing responsibility, ultimately assuming the role of President of the company’s $1.3 billion Beverage and Consumer Electronics business. Mr. Scherger is a member of the Board of Directors of Middleby Corporation (NASDAQ: MIDD), serving as a member of the Audit Committee and Chair of the Compensation Committee.

About Amcor

Amcor is the global leader in developing and producing responsible consumer packaging and dispensing solutions across a variety of materials for nutrition, health, beauty and wellness categories. Our global product innovation and sustainability expertise enables us to solve packaging challenges around the world every day, producing a range of flexible packaging, rigid packaging, cartons and closures that are more sustainable, functional and appealing for our customers and their consumers. We are guided by our purpose of elevating customers, shaping lives and protecting the future. Supported by a commitment to safety, over 75,000 people generate $23 billion in annualized sales from operations that span over 400 locations in more than 40 countries. NYSE: AMCR; ASX: AMC

www.amcor.com | LinkedIn | YouTube 

Cautionary Statement Regarding Forward-Looking Statements

Unless otherwise indicated, references to “Amcor,” the “Company,” “we,” “our,” and “us” in this document refer to Amcor plc and its consolidated subsidiaries. This document contains certain statements that are “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are generally identified with words like “believe,” “expect,” “target,” “project,” “may,” “could,” “would,” “approximately,” “possible,” “will,” “should,” “intend,” “plan,” “anticipate,” “commit,” “estimate,” “potential,” “ambitions,” “outlook,” or “continue,” the negative of these words, other terms of similar meaning, or the use of future dates. Such statements are based on the current expectations of the management of Amcor and are qualified by the inherent risks and uncertainties surrounding future expectations generally. Actual results could differ materially from those currently anticipated due to a number of risks and uncertainties. Neither Amcor nor any of its respective directors, executive officers, or advisors, provide any representation, assurance, or guarantee that the occurrence of the events expressed or implied in any forward-looking statements will actually occur or if any of them do occur, what impact they will have on the business, results of operations or financial condition of Amcor. Should any risks and uncertainties develop into actual events, these developments could have a material adverse effect on Amcor’s business, including the ability to successfully realize the expected benefits of the merger of Amcor and Berry Global Group, Inc. Risks and uncertainties that could cause actual results to differ from expectations include, but are not limited to: risks arising from the integration of the Amcor and Berry Global Group, Inc., (“Berry Global”) businesses as a result of the Merger completed on April 30, 2025 (the “Transaction”); risk of continued substantial and unexpected costs or expenses resulting from the Transaction; risk that the anticipated benefits of the Transaction may not be realized when expected or at all; risk that the Company’s significant indebtedness may limit its flexibility and increase its borrowing costs; risk that the Merger related tax liabilities could have a material impact on the Company’s financial results; changes in consumer demand patterns and customer requirements in numerous industries; risk of loss of key customers, a reduction in their production requirements, or consolidation among key customers; significant competition in the industries and regions in which we operate; an inability to expand our current business effectively through either organic growth, including product innovation, investments, or acquisitions; challenging global economic conditions; impacts of operating internationally; price fluctuations or shortages in the availability of raw materials, energy and other inputs, which could adversely affect our business; production, supply, and other commercial risks, including counterparty credit risks, which may be exacerbated in times of economic volatility; pandemics, epidemics, or other disease outbreaks; an inability to attract, develop, and retain our skilled workforce and manage key officer and employee transitions; labor disputes and an inability to renew collective bargaining agreements at acceptable terms; physical impacts of climate change; significant disruption at key manufacturing facilities; cybersecurity risks, which could disrupt our operations or risk of loss of our sensitive business information; failures or disruptions in our information technology systems which could disrupt our operations, compromise customer, employee, supplier, and other data; rising interest rates that increase our borrowing costs on our variable rate indebtedness and could have other negative impacts; foreign exchange rate risk; a significant write-down of goodwill and/or other intangible assets; a failure to maintain an effective system of internal control over financial reporting; an inability of our insurance policies, including our use of a captive insurance company, to provide adequate protection against all of the key operational risks we face; an inability to defend our intellectual property rights or intellectual property infringement claims against us; litigation, including product liability claims or litigation related to Environmental, Social, and Governance (“ESG”) matters, or regulatory developments; increasing scrutiny and changing expectations from investors, customers, suppliers, and governments with respect to our ESG practices and commitments resulting in additional costs or exposure to additional risks; changing ESG government regulations including climate-related rules; changing environmental, health, and safety laws; changes in tax laws or changes in our geographic mix of earnings; and changes in trade policy, including tariff and custom regulations or failing to comply with such regulations. These risks and uncertainties are supplemented by those identified from time to time in our filings with the Securities and Exchange Commission (the “SEC”), including without limitation, those described under Part I, “Item 1A – Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended June 30, 2025, and as updated by our quarterly reports on Form 10-Q. You can obtain copies of Amcor’s filings with the SEC for free at the SEC’s website (www.sec.gov). Forward-looking statements included herein are made only as of the date hereof and Amcor does not undertake any obligation to update any forward-looking statements, or any other information in this communication, as a result of new information, future developments or otherwise, or to correct any inaccuracies or omissions in them which become apparent, except as expressly required by law. All forward-looking statements in this communication are qualified in their entirety by this cautionary statement.

Presentation of non-GAAP information

Included in this release are measures of financial performance that are not calculated in accordance with U.S. GAAP, including adjusted earnings per share and adjusted free cash flow. In arriving at these non-GAAP measures, we exclude items that either have a non-recurring impact on the income statement or which, in the judgment of our management, are items that, either as a result of their nature or size, could, were they not singled out, potentially cause investors to extrapolate future performance from an improper base. Management has used and uses these measures internally for planning, forecasting and evaluating the performance of the Company’s reporting segments and certain of the measures are used as a component of Amcor’s Board of Directors’ measurement of Amcor’s performance for incentive compensation purposes. Amcor believes that these non-GAAP measures are useful to enable investors to perform comparisons of current and historical performance of the Company. These non-GAAP financial measures should not be construed as an alternative to results determined in accordance with U.S. GAAP. The Company provides guidance on a non-GAAP basis as we are unable to predict with reasonable certainty the ultimate outcome and timing of certain significant forward-looking items without unreasonable effort.  These items include but are not limited to the impact of foreign exchange translation, restructuring program costs, asset impairments, possible gains and losses on the sale of assets, certain tax related events, and difficulty in making accurate forecasts and projections in connection with the legacy Berry Global business given recency of access to all relevant information. These items are uncertain, depend on various factors, and could have a material impact on U.S. GAAP earnings and cash flow measures for the guidance period.